Literature DB >> 19233475

Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS.

Michael D Valentino1, Lucinda L Hensley, Denise Skrombolas, Pamela L McPherson, Matthew D Woolard, Thomas H Kawula, Jeffrey A Frelinger, John G Frelinger.   

Abstract

Francisella tularensis is a gram-negative intracellular bacterium that is the causative agent of tularemia. Small mammals such as rodents and rabbits, as well as some biting arthropods, serve as the main vectors for environmental reservoirs of F. tularensis. The low infectious dose, ability to aerosolize the organism, and the possibility of generating antibiotic resistant strains make F. tularensis a prime organism for use in bioterrorism. As a result, some strains of F. tularensis have been placed on the CDC category A select agent list. T cell immune responses are thought to be a critical component in protective immunity to this organism. However, investigation into the immune responses to F. tularensis has been hampered by the lack of molecularly defined epitopes. Here we report the identification of a major CD4(+) T cell epitope in C57Bl/6 (B6) mice. The murine model of F. tularensis infection is relevant as mice are a natural host for F. tularensis LVS and exhibit many of the same features of tularemia seen in humans. Using T cell hybridomas derived from B6 mice that had either been inoculated with F. tularensis and allowed to clear the infection or which had been immunized by conventional means using purified recombinant protein in adjuvant, we have identified amino acids 86-99 of the lipoprotein Tul4 (RLQWQAPEGSKCHD) as an immunodominant CD4 T cell epitope in B6 mice. This epitope is a major component of both the acute and memory responses to F. tularensis infection and can constitute as much as 20% of the responding CD4 T cells in an acute infection. Reactive T cells can also effectively enter the long-term memory T cell pool. The identification of this epitope will greatly aid in monitoring the course of F. tularensis infection and will also aid in the development of effective vaccine strategies for F. tularensis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19233475      PMCID: PMC2709240          DOI: 10.1016/j.molimm.2009.01.008

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  55 in total

1.  Nucleotide sequence and T cell epitopes of a membrane protein of Francisella tularensis.

Authors:  A Sjöstedt; G Sandström; A Tärnvik; B Jaurin
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

2.  Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies.

Authors:  J Wayne Conlan; Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee
Journal:  Microb Pathog       Date:  2003-05       Impact factor: 3.738

Review 3.  Tularemia. A pathogen in nature and a biological weapon.

Authors:  Gaylene Bouska Altman
Journal:  AAOHN J       Date:  2002-08

4.  Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity.

Authors:  Lee W Thompson; Kevin T Hogan; Jennifer A Caldwell; Richard A Pierce; Ronald C Hendrickson; Donna H Deacon; Robert E Settlage; Laurence H Brinckerhoff; Victor H Engelhard; Jeffrey Shabanowitz; Donald F Hunt; Craig L Slingluff
Journal:  J Immunother       Date:  2004 May-Jun       Impact factor: 4.456

5.  Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data.

Authors:  Denise L Doolan; Scott Southwood; Daniel A Freilich; John Sidney; Norma L Graber; Lori Shatney; Lolita Bebris; Laurence Florens; Carlota Dobano; Adam A Witney; Ettore Appella; Stephen L Hoffman; John R Yates; Daniel J Carucci; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-28       Impact factor: 11.205

6.  Live vaccine strain of Francisella tularensis: infection and immunity in mice.

Authors:  A H Fortier; M V Slayter; R Ziemba; M S Meltzer; C A Nacy
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

7.  Tularemia in BALB/c and C57BL/6 mice vaccinated with Francisella tularensis LVS and challenged intradermally, or by aerosol with virulent isolates of the pathogen: protection varies depending on pathogen virulence, route of exposure, and host genetic background.

Authors:  Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee; J Wayne Conlan
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

Review 8.  Tularemia.

Authors:  Jill Ellis; Petra C F Oyston; Michael Green; Richard W Titball
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

Review 9.  Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain.

Authors:  Karen L Elkins; Siobhán C Cowley; Catharine M Bosio
Journal:  Microbes Infect       Date:  2003-02       Impact factor: 2.700

10.  Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors.

Authors:  Siobhán C Cowley; Karen L Elkins
Journal:  J Exp Med       Date:  2003-07-28       Impact factor: 14.307

View more
  15 in total

1.  Functional evidence for TCR-intrinsic specificity for MHCII.

Authors:  Heather L Parrish; Neha R Deshpande; Jelena Vasic; Michael S Kuhns
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

2.  Identification of disulfide bond isomerase substrates reveals bacterial virulence factors.

Authors:  Guoping Ren; Matthew M Champion; Jason F Huntley
Journal:  Mol Microbiol       Date:  2014-10-20       Impact factor: 3.501

3.  Proteasomes, TAP, and endoplasmic reticulum-associated aminopeptidase associated with antigen processing control CD4+ Th cell responses by regulating indirect presentation of MHC class II-restricted cytoplasmic antigens.

Authors:  Srdjan M Dragovic; Timothy Hill; Gregory J Christianson; Sungjune Kim; Tim Elliott; Diane Scott; Derry C Roopenian; Luc Van Kaer; Sebastian Joyce
Journal:  J Immunol       Date:  2011-05-13       Impact factor: 5.422

4.  A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.

Authors:  Michael D Valentino; C Siddiq Abdul-Alim; Zachary J Maben; Denise Skrombolas; Lucinda L Hensley; Thomas H Kawula; Michelle Dziejman; Edith M Lord; Jeffrey A Frelinger; John G Frelinger
Journal:  J Immunol Methods       Date:  2011-08-18       Impact factor: 2.303

5.  Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets.

Authors:  Michael D Valentino; Zachary J Maben; Lucinda L Hensley; Matthew D Woolard; Thomas H Kawula; Jeffrey A Frelinger; John G Frelinger
Journal:  Immunology       Date:  2011-01-07       Impact factor: 7.397

Review 6.  Vaccines against tularemia.

Authors:  Eileen M Barry; Leah E Cole; Araceli E Santiago
Journal:  Hum Vaccin       Date:  2009-12-11

7.  Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Deborah D Crane; Tara D Wehrly; Joshua R Fletcher; Bradley D Jones; Catharine M Bosio
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

Review 8.  Differential Immune Response Following Intranasal and Intradermal Infection with Francisella tularensis: Implications for Vaccine Development.

Authors:  McKayla J Nicol; David R Williamson; David E Place; Girish S Kirimanjeswara
Journal:  Microorganisms       Date:  2021-04-30

9.  Immunity to Francisella.

Authors:  Siobhán C Cowley; Karen L Elkins
Journal:  Front Microbiol       Date:  2011-02-16       Impact factor: 5.640

10.  A mucosal subunit vaccine protects against lethal respiratory infection with Francisella tularensis LVS.

Authors:  Amit R Ashtekar; Jannet Katz; Qingan Xu; Suzanne M Michalek
Journal:  PLoS One       Date:  2012-11-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.